News Releases

Year

Apr 03, 2020

UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Complete Response (CR) Rate of 65% at Three Months Of those with CR, 97% and 85% of Patients Remained Free of Disease at Six and Nine Months Follow-Up, Respectively Detailed Results Presentation to be Shared Virtually via American Urological Association (AUA) in mid-May PRINCETON, N.J.

Mar 23, 2020

UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization NEW YORK --(BUSINESS WIRE)--Mar. 23, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and

Mar 06, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to

Mar 02, 2020

UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

Prescription Drug User Fee Act (PDUFA) Goal Date of April 18 th for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Experienced Commercial Team Hired and Prepared for Planned UGN-101 Approval and Launch in Q2 Conference Call and Webcast to be held Today at 8:30 AM ET NEW

Feb 25, 2020

UroGen Pharma Announces March 2020 Investor Conference Schedule

NEW YORK --(BUSINESS WIRE)--Feb. 25, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will participate in fireside chats at

Feb 24, 2020

UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020

Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Feb. 24, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve

Jan 08, 2020

UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

NEW YORK --(BUSINESS WIRE)--Jan. 8, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett , President and Chief

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on